Synthesis of Novel Medicinal Compounds for Leishmaniasis Using DNDI’s Hit Compound DNDI0003202883
Session Number
CHEM 13
Advisor(s)
Dr. John Thurmond, Illinois Mathematics and Science Academy
Discipline
Chemistry
Start Date
17-4-2024 10:45 AM
End Date
17-4-2024 11:00 AM
Abstract
Leishmaniasis is a parasitic disease that phlebotomine sandflies carry that typically affects impoverished tropical and subtropical regions, such as Africa, Latin America, the Middle East, and southern Asian countries. Currently, 98 nations have endemic leishmaniasis (Bilal Zulfiqar et al., 2017). These sandflies carry protozoan parasites which can induce fever, weight loss, swelling of the spleen and liver, and abnormal blood tests (World Health Organization, 2023).
This research explores the process of synthesizing benzoxazole amide derivatives as leishmaniasis leads. The synthesized compounds are to be processed and developed to find viable derivatives from DNDi’s hit compound DNDI0003202883 with potent in vitro and in vivo antileishmanial activity. We purified and worked up our compounds using thin-layer chromatography and column chromatography. The products were then subjected to IR and NMR testing. The aim was to create a Leishmaniasis remedy that is cost-effective, achieves high efficacy, and ensures safety for individuals with immunosuppressive conditions such as HIV, especially considering the drop in effectiveness of current treatments.
Synthesis of Novel Medicinal Compounds for Leishmaniasis Using DNDI’s Hit Compound DNDI0003202883
Leishmaniasis is a parasitic disease that phlebotomine sandflies carry that typically affects impoverished tropical and subtropical regions, such as Africa, Latin America, the Middle East, and southern Asian countries. Currently, 98 nations have endemic leishmaniasis (Bilal Zulfiqar et al., 2017). These sandflies carry protozoan parasites which can induce fever, weight loss, swelling of the spleen and liver, and abnormal blood tests (World Health Organization, 2023).
This research explores the process of synthesizing benzoxazole amide derivatives as leishmaniasis leads. The synthesized compounds are to be processed and developed to find viable derivatives from DNDi’s hit compound DNDI0003202883 with potent in vitro and in vivo antileishmanial activity. We purified and worked up our compounds using thin-layer chromatography and column chromatography. The products were then subjected to IR and NMR testing. The aim was to create a Leishmaniasis remedy that is cost-effective, achieves high efficacy, and ensures safety for individuals with immunosuppressive conditions such as HIV, especially considering the drop in effectiveness of current treatments.